Health and Healthcare

Is Amarin's Cardio Trial in Trouble?

courtesy of the U.S. Food and Drug Administration

Amarin Corp. PLC (NASDAQ: AMRN) shares dropped on Friday after the firm announced that it received notice from the U.S. Food and Drug Administration (FDA). According to the notice, the FDA plans to hold an advisory committee meeting, tentatively scheduled for November 14, 2019.

This meeting is scheduled in connection with its review of the pending supplemental new drug application (sNDA) for expansion of Vascepa (icosapent ethyl) labeling based on the Reduce-it cardiovascular outcomes study.

As a results, Amarin does not expect the FDA to take action on the sNDA by the previously announced September 28, 2019, Prescription Drug User Fee Act (PDUFA) goal date. Also, Amarin did not receive notice from the FDA of a PDUFA date extension.

The company expects that the PDUFA date will be extended, assuming a typical three-month extension, to a date in late December 2019. If so, this anticipated revised PDUFA date timing would offset three of the four months that were expected to be gained from FDA’s earlier determination to conduct a priority review of the Reduce-it sNDA.

John Thero, president and CEO of Amarin, commented:

We look forward to the planned advisory committee meeting as an opportunity to highlight the landmark REDUCE-IT data and the important role we expect Vascepa should play in the treatment of cardiovascular disease in appropriate patients. We plan to continue to work collaboratively with the FDA on the pending REDUCE-IT sNDA while we prepare for a robust launch of REDUCE-IT data assuming approval of Vascepa before the end of 2019 for a cardiovascular risk reduction indication based on REDUCE-IT.

Shares of Amarin traded down about 16% to $14.99 on Friday. The 52-week range is $2.65 to $23.91, and the consensus price target is $32.67.


Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.